# Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections

> **NCT00044746** · PHASE4 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 314 (actual)

## Conditions studied

- Diabetes Mellitus
- Diabetic Foot

## Interventions

- **DRUG:** Piperacillin/Tazobactam

## Key facts

- **NCT ID:** NCT00044746
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-10
- **Primary completion:** 2003-01
- **Final completion:** 2003-01
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2013-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044746, "Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00044746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*